

# CITATION REPORT

List of articles citing

## The Parkinson Pandemic-A Call to Action

DOI: 10.1001/jamaneurol.2017.3299  
JAMA Neurology, 2018, 75, 9-10.

**Source:** <https://exaly.com/paper-pdf/69748816/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #   | Paper  | IF | Citations |
|-----|--|----|-----------|
| 455 | The Promise of Telemedicine for Movement Disorders: an Interdisciplinary Approach. <b>2018</b> , 18, 26  |    | 57        |
| 454 | ROCK inhibition in models of neurodegeneration and its potential for clinical translation. <b>2018</b> , 189, 1-21   |    | 81        |
| 453 | Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects. <b>2018</b> , 168, 1-20  |    | 47        |
| 452 | Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease. <b>2018</b> , 112, 136-148                           |    | 85        |
| 451 | Insights into polysomnography-confirmed rapid eye movement sleep behavior disorder from new prevalence and gender data in the general population. <b>2018</b> , 41,            |    | 2         |
| 450 | An Elder Care Imperative. <b>2018</b> , 3, 469-477   |    |           |
| 449 | Computational Diagnosis of Parkinson's Disease from Speech Based on Regularization Methods. <b>2018</b> ,  |    | 2         |
| 448 | Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study. <b>2018</b> , 18, 185  |    | 19        |
| 447 | Neuroengineering and neuroprosthetics. <b>2018</b> , 2, 2398212818817499   |    | 4         |
| 446 | An early diagnosis is not the same as a timely diagnosis of Parkinson's disease. <b>2018</b> , 7,  |    | 15        |
| 445 | The Emerging Evidence of the Parkinson Pandemic. <b>2018</b> , 8, S3-S8  |    | 278       |
| 444 | Diagnostic Validation for Participants in the Washington State Parkinson Disease Registry. <b>2018</b> , 2018, 3719578   |    | 7         |
| 443 | Objective Arm Swing Analysis in Early-Stage Parkinson's Disease Using an RGB-D Camera (Kinect <sup>®</sup> ). <b>2018</b> , 8, 563-570   |    | 12        |
| 442 | Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <b>2018</b> , 17, 939-953          |    | 785       |
| 441 | Safety and effectiveness of istradefylline in patients with Parkinson's disease: interim analysis of a post-marketing surveillance study in Japan. <b>2018</b> , 19, 1635-1642 |    | 34        |
| 440 | Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease. <b>2018</b> , 33, 1760-1768   |    | 10        |
| 439 | Illuminating basal ganglia and beyond in Parkinson's disease. <b>2018</b> , 33, 1373-1375  |    | 3         |

|     |  |     |
|-----|--|-----|
| 438 | Predictors of clinically meaningful change in PDQ-39 in Parkinson's disease. <b>2018</b> , 56, 93-97   | 5   |
| 437 | Acceptance of Cognitive Games through Smart TV Applications in Patients with Parkinson's Disease. <b>2018</b> ,  | 3   |
| 436 | [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study]. <b>2018</b> , 86, 624-634                                       | 3   |
| 435 | Parkinson Matters. <b>2018</b> , 8, 495-498  | 15  |
| 434 | The "when" and "where" of $\beta$ -synucleinopathies: Insights from REM sleep behavior disorder. <b>2018</b> , 91, 435-436   | 7   |
| 433 | Special issue "Parkinson's disease". <b>2018</b> , 373, 1-7  | 7   |
| 432 | Circadian rhythms and influencing factors of xerostomia among Parkinson's disease patients. <b>2019</b> , 25, 282-289  | 7   |
| 431 | [Characteristics and dynamics of inpatient treatment of patients with Parkinson's disease in Germany : Analysis of 1.5 million patient cases from 2010 to 2015]. <b>2019</b> , 90, 167-174     | 11  |
| 430 | Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease. <b>2019</b> , 18, e13031   | 158 |
| 429 | Can infections trigger alpha-synucleinopathies?. <b>2019</b> , 168, 299-322  | 35  |
| 428 | Fine Motor Assessment With Unsupervised Learning For Personalized Rehabilitation in Parkinson Disease. <b>2019</b> , 2019, 1167-1172   | 2   |
| 427 | De ziekte van Parkinson; een update. <b>2019</b> , 35, 8-16  |     |
| 426 | Metal Chelation Therapy and Parkinson's Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs. <b>2019</b> , 9, | 25  |
| 425 | The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease. <b>2019</b> , 19, 160   | 40  |
| 424 | From dreams to parkinsonism: tracking the journey. <b>2019</b> , 142, 1850-1852  | 0   |
| 423 | . <b>2019</b> ,  | 2   |
| 422 | Dysfunction of serotonergic neurons in Parkinson's disease and dyskinesia. <b>2019</b> , 146, 259-279  | 9   |
| 421 | Gait related postural control in Parkinson's Disease. <b>2019</b> , 73, 411  |     |

|     |   |     |
|-----|---|-----|
| 420 | Exercise for Parkinson's disease. <b>2019</b> , 147, 1-44   | 21  |
| 419 | Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial. <b>2019</b> , 18, 998-1008  | 139 |
| 418 | PDVocal. <b>2019</b> ,  | 15  |
| 417 | Randomized phase I clinical trial of anti- $\alpha$ -Synuclein antibody BIIB054. <b>2019</b> , 34, 1154-1163  | 78  |
| 416 | Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation. <b>2019</b> , 126, 879-888 | 2   |
| 415 | GRP78 Level Is Altered in the Brain, but Not in Plasma or Cerebrospinal Fluid in Parkinson's Disease Patients. <b>2019</b> , 13, 697  | 13  |
| 414 | A metabolic profile of polyamines in parkinson disease: A promising biomarker. <b>2019</b> , 86, 251-263  | 28  |
| 413 | Young-onset Parkinson's disease: Its unique features and their impact on quality of life. <b>2019</b> , 65, 39-48   | 23  |
| 412 | Late aging-associated increases in L-DOPA-induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat. <b>2019</b> , 81, 190-199  | 4   |
| 411 | New Sensor and Wearable Technologies to Aid in the Diagnosis and Treatment Monitoring of Parkinson's Disease. <b>2019</b> , 21, 111-143   | 35  |
| 410 | Non-Linear Dynamical Analysis of Resting Tremor for Demand-Driven Deep Brain Stimulation. <b>2019</b> , 19,   | 8   |
| 409 | Use of human pluripotent stem cell-derived cells for neurodegenerative disease modeling and drug screening platform. <b>2019</b> , 11, 1305-1322  | 16  |
| 408 | Alpha-Synuclein Pathology and the Role of the Microbiota in Parkinson's Disease. <b>2019</b> , 13, 369  | 50  |
| 407 | The Mechanisms by Which the Ketone Body D- $\beta$ -Hydroxybutyrate May Improve the Multiple Cellular Pathologies of Parkinson's Disease. <b>2019</b> , 6, 63   | 36  |
| 406 | Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium. <b>2019</b> , 402, 121-130   | 12  |
| 405 | Tremor. <b>2019</b> , 130, 51-63  | 6   |
| 404 | Using as a platform for drug discovery from natural products in Parkinson's disease. <b>2019</b> , 10, 867-879  | 13  |
| 403 | Closed-loop deep brain stimulation based on a stream-clustering system. <b>2019</b> , 126, 187-199  | 2   |

|     |  |     |
|-----|--|-----|
| 402 | Upper limb motor pre-clinical assessment in Parkinson's disease using machine learning. <b>2019</b> , 63, 111-116  | 31  |
| 401 | Progress in neuromodulation of the brain: A role for magnetic nanoparticles?. <b>2019</b> , 177, 1-14  | 35  |
| 400 | Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and Synuclein mechanisms. <b>2019</b> , 34, 866-875   | 136 |
| 399 | Experiential Learning: Transforming Theory into Practice through the Parkinson's Disease Buddy Program. <b>2019</b> , 31, 453-465  | 5   |
| 398 | The Role of Movement Analysis in Diagnosing and Monitoring Neurodegenerative Conditions: Insights from Gait and Postural Control. <b>2019</b> , 9,   | 54  |
| 397 | Dynamics of Parkinson's Disease Multimodal Complex Treatment in Germany from 2010-2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers. <b>2019</b> , 8,                                    | 15  |
| 396 | Transplant and risk of Parkinson disease. <b>2019</b> , 63, 149-155  | 3   |
| 395 | Using Wavelets for Gait and Arm Swing Analysis. <b>2019</b> ,  | 0   |
| 394 | Long-Term Partnerships in Lewy Body Dementias. <b>2019</b> ,   | 1   |
| 393 | Wearable Sensors for Prodromal Motor Assessment of Parkinson's Disease using Supervised Learning. <b>2019</b> , 2019, 4318-4321  | 4   |
| 392 | A low-cost vision system based on the analysis of motor features for recognition and severity rating of Parkinson's Disease. <b>2019</b> , 19, 243   | 17  |
| 391 | Reporting and methodological quality of clinical trials on exercise therapy for Parkinson's disease. <b>2019</b> , 69, 150-156   | 4   |
| 390 | The Challenge and Opportunity to Diagnose Parkinson's Disease in Midlife. <b>2019</b> , 10, 1328   | 7   |
| 389 | Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis. <b>2019</b> , 42, 4-13   | 138 |
| 388 | A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. <b>2019</b> , 9, 31-61  | 33  |
| 387 | The risk of neurodegeneration in REM sleep behavior disorder: A systematic review and meta-analysis of longitudinal studies. <b>2019</b> , 43, 37-46   | 92  |
| 386 | Cell therapy for Parkinson's disease is coming of age: current challenges and future prospects with a focus on immunomodulation. <b>2020</b> , 27, 6-14  | 9   |
| 385 | [Trends in the Prevalence of Dementia and Parkinson's Disease: An Analysis Based on Health Claims Data from all German Statutory Health Insurance Funds for Persons aged 65+in Germany 2009-2012]. <b>2020</b> , 82, 761-769 | 6   |

|     |  |     |
|-----|--|-----|
| 384 | The genetic architecture of Parkinson's disease. <b>2020</b> , 19, 170-178   | 261 |
| 383 | MRI biomarkers of motor and non-motor symptoms in Parkinson's disease. <b>2020</b> , 73, 85-93   | 10  |
| 382 | Methodologies and Intelligent Systems for Technology Enhanced Learning, 9th International Conference, Workshops. <b>2020</b> ,   | 1   |
| 381 | Effectiveness of SaeboreJoyce in the Evaluation of the Improvement of the Occupational Performance in Parkinson's Disease: An Outcome Research. <b>2020</b> , 63-70  | 0   |
| 380 | The Mini-BESTest is an independent predictor of falls in Parkinson Disease. <b>2020</b> , 24, 433-440  | 6   |
| 379 | The Perioperative Medicine Consult Handbook. <b>2020</b> ,   |     |
| 378 | Emerging concepts of mitochondrial dysfunction in Parkinson's disease progression: Pathogenic and therapeutic implications. <b>2020</b> , 50, 25-34  | 30  |
| 377 | Synthesis and evaluation of methoxy substituted 2-benzoyl-1-benzofuran derivatives as lead compounds for the development adenosine A and/or A receptor antagonists. <b>2020</b> , 94, 103459                       | 5   |
| 376 | Genome-wide identification of mA-associated single-nucleotide polymorphisms in Parkinson's disease. <b>2020</b> , 737, 135315  | 9   |
| 375 | No enhanced (p-) $\beta$ -synuclein deposition in gastrointestinal tissue of Parkinson's disease patients. <b>2020</b> , 80, 82-88   | 6   |
| 374 | Parkin-linked Parkinson's disease: From clinical insights to pathogenic mechanisms and novel therapeutic approaches. <b>2020</b> , 159, 34-39  | 6   |
| 373 | The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. <b>2020</b> , 5, e551-e567   | 101 |
| 372 | Synergy of pandemics-social isolation is associated with worsened Parkinson severity and quality of life. <b>2020</b> , 6, 28  | 30  |
| 371 | Comparison of effectiveness of trihexyphenidyl and levodopa on motor symptoms in Parkinson's disease. <b>2020</b> , 127, 1599-1606   | 2   |
| 370 | Parkinson Network Eastern Saxony (PANOS): Reaching Consensus for a Regional Intersectoral Integrated Care Concept for Patients with Parkinson's Disease in the Region of Eastern Saxony, Germany. <b>2020</b> , 9, | 5   |
| 369 | Melatonin secretion in patients with Parkinson's disease receiving different-dose levodopa therapy. <b>2020</b> , 75, 309-314  | 3   |
| 368 | The Role of the Primary Care Provider in Work-up and Management of Parkinson Disease. <b>2020</b> , 2, 37-47   | 1   |
| 367 | Validation of Parkinson's Disease-Related Questionnaires in South Africa. <b>2020</b> , 2020, 7542138  | 4   |

|     |   |    |
|-----|---|----|
| 366 | Mutation Analysis of DNAJC Family for Early-Onset Parkinson's Disease in a Chinese Cohort. <b>2020</b> , 35, 2068-2076  | 8  |
| 365 | Parkinson's gait kinematics deteriorates across multiple cognitive domains under dual-task paradigms. <b>2020</b> , 197, 106083   | 2  |
| 364 | What People with Parkinson's Disease Want. <b>2020</b> , 10, S5-S10   | 8  |
| 363 | Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned. <b>2020</b> , 17, 1393-1405  | 9  |
| 362 | The Underlying Mechanism of Pall. in Parkinson's Disease Based on a Network Pharmacology Approach. <b>2020</b> , 11, 581984   | 12 |
| 361 | Peripheral Glycolysis in Neurodegenerative Diseases. <b>2020</b> , 21,  | 10 |
| 360 | Diagnóstico y abordaje de las alteraciones asociadas a la enfermedad de Parkinson en atención primaria. <b>2020</b> , 27, 293-299   |    |
| 359 | Prototipos de personalidad que predicen el malestar psicológico del cuidador. <b>2020</b> , 12, 254-259   | 0  |
| 358 | Smart Tracking and Wearables: Techniques in Gait Analysis and Movement in Pathological Aging. <b>2020</b> ,   | 2  |
| 357 | The effects of intensive speech treatment on intelligibility in Parkinson's disease: A randomised controlled trial. <b>2020</b> , 24, 100429  | 17 |
| 356 | Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020. <b>2020</b> , 10, 757-774  | 47 |
| 355 | Analysis of rare variants of autosomal-dominant genes in a Chinese population with sporadic Parkinson's disease. <b>2020</b> , 8, e1449   | 3  |
| 354 | Gut Microbiota Approach-A New Strategy to Treat Parkinson's Disease. <b>2020</b> , 10, 570658   | 14 |
| 353 | K channel blockage with 3,4-diaminopyridine potentiates the effect of L-DOPA on dopamine release in striatal slices prepared from 6-OHDA pre-treated rats. <b>2020</b> , 238, 2539-2548 | 1  |
| 352 | Automatic Gait Phases Detection in Parkinson Disease: A Comparative Study. <b>2020</b> , 2020, 798-802  | 4  |
| 351 | Identifying Risk Genes and Interpreting Pathogenesis for Parkinson's Disease by a Multiomics Analysis. <b>2020</b> , 11,  | 1  |
| 350 | Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson's disease. <b>2020</b> , 6, 21  | 4  |
| 349 | The Potential Role of SARS-COV-2 in the Pathogenesis of Parkinson's Disease. <b>2020</b> , 11, 1044   | 18 |

|     |   |    |
|-----|---|----|
| 348 | Extracellular Vesicles as Nanotherapeutics for Parkinson's Disease. <b>2020</b> , 10,   | 5  |
| 347 | Therapeutic strategies for Parkinson's disease: promising agents in early clinical development. <b>2020</b> , 29, 1249-1267   | 6  |
| 346 | The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results. <b>2020</b> , 127, 1343-1358      | 7  |
| 345 | Building a Parkinson-Network-Experiences from Germany. <b>2020</b> , 9,   | 2  |
| 344 | The Role of Architecture and Design in the Management of Parkinson's Disease: A Systematic Review. <b>2020</b> , 10, 1301-1314  | 3  |
| 343 | Current Perspectives on Aerobic Exercise in People with Parkinson's Disease. <b>2020</b> , 17, 1418-1433  | 15 |
| 342 | Genetic Risk Profiling in Parkinson's Disease and Utilizing Genetics to Gain Insight into Disease-Related Biological Pathways. <b>2020</b> , 21,  | 9  |
| 341 | Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study. <b>2020</b> , 47, 8997-9004 | 4  |
| 340 | Dopaminergic modulation of novelty repetition in Parkinson's disease: A study of P3 event-related brain potentials. <b>2020</b> , 131, 2841-2850  | 5  |
| 339 | A Multi-Sensor Wearable System for the Quantitative Assessment of Parkinson's Disease. <b>2020</b> , 20,  | 5  |
| 338 | Synuclein Oligomer Detection with Aptamer Switch on Reduced Graphene Oxide Electrode. <b>2020</b> , 10,   | 14 |
| 337 | Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: A randomized, double-blind, placebo-controlled trial. <b>2020</b> , 195, 105878      | 17 |
| 336 | Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease-Viewpoint. <b>2020</b> , 11, 556  | 7  |
| 335 | Immunization therapies for Parkinson's disease: state of the art and considerations for future clinical trials. <b>2020</b> , 29, 685-695   | 13 |
| 334 | COVID-19 and Parkinson's Disease: Are We Dealing with Short-term Impacts or Something Worse?. <b>2020</b> , 10, 899-902   | 16 |
| 333 | Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson's disease patients: an European multicentre survey. <b>2020</b> , 127, 875-879          | 8  |
| 332 | Self-Management Education for Persons with Parkinson's Disease and Their Care Partners: A Quasi-Experimental Case-Control Study in Clinical Practice. <b>2020</b> , 2020, 6920943       | 9  |
| 331 | Domperidone in Parkinson's disease: a valuable controversy, but unnecessary panic. <b>2020</b> , 37, 723-724  |    |



|     |   |     |
|-----|---|-----|
| 330 | Remote telemedicine evaluation of deep brain stimulation candidacy: Retrospective cohort analysis. <b>2020</b> , 10, 199-205  | 10  |
| 329 | ParkinSong: Outcomes of a 12-Month Controlled Trial of Therapeutic Singing Groups in Parkinson's Disease. <b>2020</b> , 10, 1217-1230                               | 7   |
| 328 | Measuring Medication Adherence in Parkinson's Disease: A Systematic Review of Contributing Components in Rating Scales. <b>2020</b> , 7, 607-615                    | 4   |
| 327 | Translation Imaging in Parkinson's Disease: Focus on Neuroinflammation. <b>2020</b> , 12, 152   | 18  |
| 326 | The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson's Disease. <b>2020</b> , 10,   | 4   |
| 325 | Could <i>Mucuna pruriens</i> be the answer to Parkinson's disease management in sub-Saharan Africa and other low-income countries worldwide?. <b>2020</b> , 73, 3-7 | 7   |
| 324 | Analysis of DNA methylation associates the cystine-glutamate antiporter SLC7A11 with risk of Parkinson's disease. <b>2020</b> , 11, 1238                            | 25  |
| 323 | Experiences of advance care planning in Parkinson's disease and atypical parkinsonian disorders: a mixed methods systematic review. <b>2020</b> , 27, 1971-1987     | 8   |
| 322 | Chasing Protection in Parkinson's Disease: Does Exercise Reduce Risk and Progression?. <b>2020</b> , 12, 186  | 12  |
| 321 | Parkinson's disease: etiopathogenesis and treatment. <b>2020</b> , 91, 795-808  | 120 |
| 320 | Translation, Validation, Diagnostic Accuracy, and Reliability of Screening Questionnaire for Parkinsonism in Three African Countries. <b>2020</b> , 10, 1113-1122   | 1   |
| 319 | Challenges and Perspectives in the Management of Late-Stage Parkinson's Disease. <b>2020</b> , 10, S75-S83  | 8   |
| 318 | The discerning eye of computer vision: Can it measure Parkinson's finger tap bradykinesia?. <b>2020</b> , 416, 117003   | 21  |
| 317 | Quality Improvement in Parkinson's Disease: A Successful Program to Enhance Timely Administration of Levodopa in the Hospital. <b>2020</b> , 10, 1551-1559          |     |
| 316 | Motor-cognitive approach and aerobic training: a synergism for rehabilitative intervention in Parkinson's disease. <b>2020</b> , 10, 41-55                          | 15  |
| 315 | Uncovering the Pharmacological Mechanism of Stemazole in the Treatment of Neurodegenerative Diseases Based on a Network Pharmacology Approach. <b>2020</b> , 21,    | 9   |
| 314 | Trichloroethylene, a ubiquitous environmental contaminant in the risk for Parkinson's disease. <b>2020</b> , 22, 543-554  | 12  |
| 313 | Exosomes derived from mesenchymal stem cells repair a Parkinson's disease model by inducing autophagy. <b>2020</b> , 11, 288  | 48  |

|     |   |    |
|-----|---|----|
| 312 | Structural Characterization of Individual $\beta$ Synuclein Oligomers Formed at Different Stages of Protein Aggregation by Atomic Force Microscopy-Infrared Spectroscopy. <b>2020</b> , 92, 6806-6810 | 26 |
| 311 | Novel approaches to counter protein aggregation pathology in Parkinson's disease. <b>2020</b> , 252, 451-492  | 4  |
| 310 | Endosomal sorting pathways in the pathogenesis of Parkinson's disease. <b>2020</b> , 252, 271-306   | 8  |
| 309 | Effects of self-management education for persons with Parkinson's disease and their care partners: A qualitative observational study in clinical care. <b>2020</b> , 22, 741-748                      | 7  |
| 308 | Treating Patients Like Athletes: Sports Science Applied to Parkinson's Disease. <b>2020</b> , 11, 228   | 1  |
| 307 | Applied cognitive strategy behaviours in people with parkinson's disease during daily activities: A cross-sectional study. <b>2019</b> , 52, jrm00010   | 1  |
| 306 | Integrated Metabolomics and Proteomics Analysis Reveals Plasma Lipid Metabolic Disturbance in Patients With Parkinson's Disease. <b>2020</b> , 13, 80   | 17 |
| 305 | Evolution of Initial Pharmacologic Treatment of Newly Diagnosed Parkinson's Disease Patients over a Decade in Singapore. <b>2020</b> , 2020, 6293124  | 1  |
| 304 | mHealth Technologies Towards Parkinson's Disease Detection and Monitoring in Daily Life: A Comprehensive Review. <b>2021</b> , 14, 71-81  | 8  |
| 303 | Probiotic <i>Clostridium butyricum</i> ameliorated motor deficits in a mouse model of Parkinson's disease via gut microbiota-GLP-1 pathway. <b>2021</b> , 91, 703-715                                 | 31 |
| 302 | Preliminary Findings on Proline-Rich Protein 14 as a Diagnostic Biomarker for Parkinson's Disease. <b>2021</b> , 23, 285-291  | 0  |
| 301 | Health behaviors a year after an early intervention exercise and education program for people with Parkinson's disease. <b>2021</b> , 11, 65-75   | 3  |
| 300 | Reliability and Validity of Pupillary Response During Dual-Task Balance in Parkinson Disease. <b>2021</b> , 102, 448-455  | 3  |
| 299 | Clinical Non-Motor Phenotyping of Black and Asian Minority Ethnic Compared to White Individuals with Parkinson's Disease Living in the United Kingdom. <b>2021</b> , 11, 299-307                      | 6  |
| 298 | From trials to clinical practice: Temporal trends in the coverage of specialized allied health services for Parkinson's disease. <b>2021</b> , 28, 775-782  | 2  |
| 297 | Dammarane triterpenes targeting $\beta$ Synuclein: biological activity and evaluation of binding sites by molecular docking. <b>2021</b> , 36, 154-162  | 2  |
| 296 | Leg Muscle Strength Correlates with Gait Performance in Advanced Parkinson Disease. <b>2021</b> ,   |    |
| 295 | Is the Food Good for Me and the Planet?. <b>2021</b> , 331-360  |    |

|     |   |    |
|-----|---|----|
| 294 | Etiology and pathogenesis of Parkinson disease. <b>2021</b> , 121-163.e16   | 1  |
| 293 | Measurement of LRRK2 Kinase Activity by Proximity Ligation Assay. <b>2021</b> , 11, e4140   | 2  |
| 292 | Evaluation for Parkinsonian Bradykinesia by deep learning modeling of kinematic parameters. <b>2021</b> , 128, 181-189  | 1  |
| 291 | Designs to Detect Disease Modification. <b>2021</b> , 1-20  |    |
| 290 | Advanced brain ageing in Parkinson's disease is related to disease duration and individual impairment. <b>2021</b> , 3, fcab191   | 2  |
| 289 | Effectiveness of a Long-Term, Home-Based Aerobic Exercise Intervention on Slowing the Progression of Parkinson Disease: Design of the Cyclical Lower Extremity Exercise for Parkinson Disease II (CYCLE-II) Study. <b>2021</b> , 101, | 1  |
| 288 | An Update on Medical and Surgical Treatments of Parkinson's Disease. <b>2021</b> , 12, 1021-1035  | 2  |
| 287 | Neuroprotective effects of San-Jia-Fu-Mai decoction: Studies on the in vitro and in vivo Models of Parkinson's Disease. <b>2021</b> ,   | 0  |
| 286 | Osteoporosis in neurological disorders: Parkinson's disease, stroke, and multiple sclerosis. <b>2021</b> , 1033-1059  |    |
| 285 | Parkinson's Disease Detection from Voice and Speech Data Using Machine Learning. <b>2021</b> , 445-456  | 1  |
| 284 | The Cytotoxic Effect of $\alpha$ -Synuclein Aggregates. <b>2021</b> , 22, 526-532   | 1  |
| 283 | Invertebrate Models Untangle the Mechanism of Neurodegeneration in Parkinson's Disease. <b>2021</b> , 10,   | 5  |
| 282 | A simple-to-use web-based calculator for survival prediction in Parkinson's disease. <b>2021</b> , 13, 5238-5249  | 4  |
| 281 | Microemulsion-Based Media in Nose-to-Brain Drug Delivery. <b>2021</b> , 13,   | 14 |
| 280 | Implementation of high-cadence cycling for Parkinson's disease in the community setting: A pragmatic feasibility study. <b>2021</b> , 11, e02053  | 3  |
| 279 | Surgical Management of Parkinson's Disease in the Elderly. <b>2021</b> , 8, 500-509   | 0  |
| 278 | Differences in MTHFR and LRRK2 variant's association with sporadic Parkinson's disease in Mexican Mestizos correlated to Native American ancestry. <b>2021</b> , 7, 13  | 0  |
| 277 | The Importance of Research to Uncover Cellular Pathways Underlying Parkinson's Disease. <b>2021</b> , 10,   | 7  |

|     |   |    |
|-----|---|----|
| 276 | Nutritional aspects in Parkinson's disease. <b>2021</b> , 1-18  |    |
| 275 | Combined Knockout of Lrrk2 and Rab29 Does Not Result in Behavioral Abnormalities in vivo. <b>2021</b> , 11, 569-584   | 4  |
| 274 | Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review. <b>2021</b> , 11, 475-489   | 4  |
| 273 | Pelvic Floor Health in Women with Parkinson's Disease. <b>2021</b> , 11, 857-864  | 2  |
| 272 | Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease. <b>2021</b> , 377, 407-416  | 1  |
| 271 | Applications of brain organoids in neurodevelopment and neurological diseases. <b>2021</b> , 28, 30   | 8  |
| 270 | The Impact of Exercise Intervention with Rhythmic Auditory Stimulation to Improve Gait and Mobility in Parkinson Disease: An Umbrella Review. <b>2021</b> , 11,               | 1  |
| 269 | Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. <b>2021</b> , 53, 787-793                  | 15 |
| 268 | Short-chain fatty acids-producing probiotics: A novel source of psychobiotics. <b>2021</b> , 1-31   | 5  |
| 267 | Effect of Aerobic Exercise on Cardiopulmonary Responses and Predictors of Change in Individuals With Parkinson's Disease. <b>2021</b> , 102, 925-931                          | 3  |
| 266 | Electromyography-informed modeling for estimating muscle activation and force alterations in Parkinson's disease. <b>2021</b> , 1-13  | 1  |
| 265 | FGF, Mechanism of Action, Role in Parkinson's Disease, and Therapeutics. <b>2021</b> , 12, 675725   | 2  |
| 264 | Parkinson disease risks: correctly identifying environmental factors for a chronic disease. <b>2021</b> , 131,  | 0  |
| 263 | Regulatory miRNA-mRNA Networks in Parkinson's Disease. <b>2021</b> , 10,  | 2  |
| 262 | Availability of Therapies and Services for Parkinson's Disease in Africa: A Continent-Wide Survey. <b>2021</b> , 36, 2393-2407  | 2  |
| 261 | Salvianolic acid B protects against MPP <sup>+</sup> -induced neuronal injury via repressing oxidative stress and restoring mitochondrial function. <b>2021</b> , 32, 815-823 | 3  |
| 260 | High intensity aerobic exercise improves bimanual coordination of grasping forces in Parkinson's disease. <b>2021</b> , 87, 13-19   | 2  |
| 259 | The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease. <b>2021</b> , 153, 105312    | 6  |

|     |  |        |
|-----|--|--------|
| 258 | Opicapone for Parkinson's disease: clinical evidence and future perspectives. <b>2021</b> , 11, 193-206  | 0      |
| 257 | Towards Parkinson's Disease Prognosis Using Self-Supervised Learning and Anomaly Detection. <b>2021</b> ,  | 1      |
| 256 | Behavioral Phenotyping in a Murine Model of $\alpha$ -Synuclein-Associated Parkinson Disease. <b>2021</b> , 22,  | 0      |
| 255 | Bilirubin: A Promising Therapy for Parkinson's Disease. <b>2021</b> , 22,  | 0      |
| 254 | The impact of tube replacement timing during LCIG therapy on PEG-J associated adverse events: a retrospective multicenter observational study. <b>2021</b> , 21, 242                           | 1      |
| 253 | A New Era: The Growth of Video-Based Visits for Remote Management of Persons with Parkinson's Disease. <b>2021</b> , 11, S27-S34   | 8      |
| 252 | Monitoring Parkinson's disease progression based on recorded speech with missing ordinal responses and replicated covariates. <b>2021</b> , 134, 104503  | 0      |
| 251 | The role of support groups in the management of Parkinson's disease in Kenya: Sociality, information and legitimacy. <b>2021</b> , 1-11  | 0      |
| 250 | Parkinson disease-associated cognitive impairment. <b>2021</b> , 7, 47   | 55     |
| 249 | Dopamine neuron-specific LRRK2 G2019S effects on gene expression revealed by transcriptome profiling. <b>2021</b> , 155, 105390  | 1      |
| 248 | Possible Link between SARS-CoV-2 Infection and Parkinson's Disease: The Role of Toll-Like Receptor 4. <b>2021</b> , 22,  | 3      |
| 247 | LncRNA MALAT1 potentiates inflammation disorder in Parkinson's disease. <b>2021</b> , 48, 419-428  | 2      |
| 246 | Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic $\alpha$ -Synuclein oligomers in Parkinson's disease. <b>2021</b> , 1                                | 7      |
| 245 | Feasibility of a Mobile-Based System for Unsupervised Monitoring in Parkinson's Disease. <b>2021</b> , 21,   | 1      |
| 244 | Reappraisal of metabolic dysfunction in neurodegeneration: Focus on mitochondrial function and calcium signaling. <b>2021</b> , 9, 124   | 8      |
| 243 | SIRT1 Protects Dopaminergic Neurons in Parkinson's Disease Models via PGC-1 $\alpha$ -Mediated Mitochondrial Biogenesis. <b>2021</b> , 39, 1393-1404   | 4      |
| 242 | Home Health Management of Parkinson Disease Deep Brain Stimulation: A Randomized Clinical Trial. <i>JAMA Neurology</i> , <b>2021</b> , 78, 972-981   | 17.2 4 |
| 241 | Myrtenol complexed with $\beta$ -cyclodextrin ameliorates behavioural deficits and reduces oxidative stress in the reserpine-induced animal model of Parkinsonism. <b>2021</b> , 48, 1488-1499 | 3      |

|     |  |   |
|-----|--|---|
| 240 | A Systematic Review and Meta-analysis of Iowa Oral Performance Instrument Measures in Persons with Parkinson's Disease Compared to Healthy Adults. <b>2021</b> , 1   | 1 |
| 239 | Methodological Issues in Randomized Clinical Trials for Prodromal Alzheimer's and Parkinson's Disease. <b>2021</b> , 12, 694329  | 2 |
| 238 | Dopamine D3 Receptor Ligand Suppresses the Expression of Levodopa-Induced Dyskinesia in Nonhuman Primate Model of Parkinson's Disease.   | 1 |
| 237 | Genetic Analysis and Literature Review of Variants in Parkinson's Disease. <b>2021</b> , 13, 648151  | 1 |
| 236 | Advance Care Planning and Care Coordination for People With Parkinson's Disease and Their Family Caregivers-Study Protocol for a Multicentre, Randomized Controlled Trial. <b>2021</b> , 12, 673893          | 2 |
| 235 | High-fat diet-induced diabetes leads to vascular alterations, pericyte reduction, and perivascular depletion of microglia in a 6-OHDA toxin model of Parkinson disease. <b>2021</b> , 18, 175                | 4 |
| 234 | "Old people problems", uncertainty and legitimacy: Challenges with diagnosing Parkinson's disease in Kenya. <b>2021</b> , 282, 114148  | 1 |
| 233 | Six-Month Community-Based Brisk Walking and Balance Exercise Alleviates Motor Symptoms and Promotes Functions in People with Parkinson's Disease: A Randomized Controlled Trial. <b>2021</b> , 11, 1431-1441 | 5 |
| 232 | Combined Metabolic Activators Improve Cognitive Functions without Altering Motor Scores in Parkinson's Disease.  | 1 |
| 231 | Effectiveness of Long-Term Physiotherapy in Parkinson's Disease: A Systematic Review and Meta-Analysis. <b>2021</b> , 11, 1619-1630  | 1 |
| 230 | Rating scales for medication adherence in people living with Parkinson's disease: a systematic review protocol. <b>2021</b> ,  | 0 |
| 229 | ATH434 Reverses Colorectal Dysfunction in the A53T Mouse Model of Parkinson's Disease. <b>2021</b> , 11, 1821-1832   | 3 |
| 228 | A Multi-Step Model of Parkinson's Disease Pathogenesis. <b>2021</b> , 36, 2530-2538  | 5 |
| 227 | Noninvasive vagus nerve stimulation in Parkinson's disease: current status and future prospects. <b>2021</b> , 18, 971-984   | 0 |
| 226 | Nursing and Parkinson's Disease: A Scoping Review of Worldwide Studies. <b>2021</b> , 10547738211044047  | 2 |
| 225 | The disturbance of lipid metabolism is correlated with neuropsychiatric symptoms in patients with Parkinson's disease. <b>2021</b> , 239, 105112   | 2 |
| 224 | Circadian activity rhythm in Parkinson's disease: findings from the PHASE study. <b>2021</b> , 85, 8-14  | 2 |
| 223 | Protective role of selenium on MPP and homocysteine-induced TRPM2 channel activation in SH-SY5Y cells. <b>2021</b> , 1-10  | 2 |

|     |  |    |
|-----|--|----|
| 222 | All Roads Lead to Rome: Different Molecular Players Converge to Common Toxic Pathways in Neurodegeneration. <b>2021</b> , 10,  | 2  |
| 221 | Association analysis and polygenic risk score evaluation of 38 GWAS-identified Loci in a Chinese population with Parkinson's disease. <b>2021</b> , 762, 136150  | 1  |
| 220 | "No One Can Tell Me How Parkinson's Disease Will Unfold": A Mixed Methods Case Study on Palliative Care for People with Parkinson's Disease and Their Family Caregivers. <b>2021</b> ,                         |    |
| 219 | Application of AI for Analysis of Parkinson's Disease. <b>2021</b> , 11, 33-39   |    |
| 218 | Dietary patterns affect Parkinson's disease via the microbiota-gut-brain axis. <b>2021</b> , 116, 90-101   | 5  |
| 217 | Influence of istradefylline on non-motor symptoms of Parkinson's disease: A subanalysis of a 1-year observational study in Japan (J-FIRST). <b>2021</b> , 91, 115-120  | 0  |
| 216 | Efficacy of short-term multidisciplinary intensive rehabilitation in patients with different Parkinson's disease motor subtypes: a prospective pilot study with 3-month follow-up. <b>2021</b> , 16, 1336-1343 | 1  |
| 215 | Progress in generating iPSC-derived dopaminergic neurons as accurate models of neurodegenerative disease. <b>2021</b> , 181-203  |    |
| 214 | RBD: Future Directions in Research and Clinical Care and Counseling. <b>2019</b> , 649-663   | 1  |
| 213 | Recurrent falls in people with Parkinson's disease. <b>2020</b> , 157-183  | 1  |
| 212 | Repurposing GLP1 agonists for neurodegenerative diseases. <b>2020</b> , 155, 91-112  | 3  |
| 211 | The late stage of Parkinson's -results of a large multinational study on motor and non-motor complications. <b>2020</b> , 75, 91-96  | 14 |
| 210 | Integrated and patient-centred management of Parkinson's disease: a network model for reshaping chronic neurological care. <b>2020</b> , 19, 623-634   | 51 |
| 209 | Cognitive decline in Parkinson's disease is associated with reduced complexity of EEG at baseline. <b>2020</b> , 2, fcaa207  | 2  |
| 208 | Unhealthy Behaviours and Parkinson's Disease: A Mendelian Randomisation Study.   | 1  |
| 207 | Parkinson disease age of onset GWAS: defining heritability, genetic loci and a-synuclein mechanisms.   | 6  |
| 206 | Machine learning-assisted neurotoxicity prediction in human midbrain organoids.  | 3  |
| 205 | Parkinson's disease, aging and adult neurogenesis: Wnt/ $\beta$ -catenin signalling as the key to unlock the mystery of endogenous brain repair. <b>2020</b> , 19, e13101                                      | 43 |

|     |  |   |
|-----|--|---|
| 204 | The Ronnie Gardiner Method: An Innovative Music-Based Intervention for Neurological Rehabilitation - Theoretical Background and Contemporary Research with Focus on Parkinson's Disease. <b>2018</b> , 32-37 | 1 |
| 203 | Iron Dysregulation and Inflammagens Related to Oral and Gut Health Are Central to the Development of Parkinson's Disease. <b>2020</b> , 11,  | 7 |
| 202 | Axillary Microbiota is Associated with Cognitive Impairment in Parkinson's Disease Patients.   |   |
| 201 | The effects of metallothionein in paraquat-induced Parkinson disease model of zebrafish. <b>2021</b> , 1-12  | 0 |
| 200 | The potential neuroprotective effect of diosmin in rotenone-induced model of Parkinson's disease in rats. <b>2021</b> , 174573   | 3 |
| 199 | Polygenic Risk Scores Contribute to Personalized Medicine of Parkinson's Disease. <b>2021</b> , 11,  | 2 |
| 198 | Biomaterial Strategies for Restorative Therapies in Parkinson's Disease. <b>2021</b> , 12, 4224-4235   | 2 |
| 197 | Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson's Disease. <b>2021</b> ,   | 3 |
| 196 | Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications. <b>2021</b> , 92, 59-66                 | 4 |
| 195 | Are ion channels potential therapeutic targets for Parkinson's disease?. <b>2021</b> , 87, 243-257   | 1 |
| 194 | Parkinson's Disease Animal Models. 3,  |   |
| 193 | Current Treatments for Parkinson's Disease. <b>2019</b> , 56, 180-184  |   |
| 192 | Parkinson's Disease. <b>2020</b> , 247-258   |   |
| 191 | Multimodal Training Reduces Fall Frequency as Physical Activity Increases in Individuals With Parkinson's Disease. <b>2019</b> , 16, 1085-1091   | 4 |
| 190 | Combined knockout of Lrrk2 and Rab29 does not result in behavioral abnormalities in vivo.  | 2 |
| 189 | Preventing Parkinson's Disease: An Environmental Agenda. <b>2021</b> ,   | 7 |
| 188 | Neuroinflammation in Parkinson's disease: a meta-analysis of PET imaging studies. <b>2021</b> , 1  | 1 |
| 187 | Management with antibiotics in Parkinson's disease. <b>2020</b> , 491-510  | 0 |



- 186 Occupational Therapy in the Community. **2020**, 33-54
- 185 Dopamine D3 receptor ligand suppresses the expression of levodopa-induced dyskinesia in nonhuman primate model of parkinson's disease. **2022**, 347, 113920
- 184 The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease. 0
- 183 Cohort profile: Design and implementation of the Danish Physiotherapy Research Database for patients receiving primary care with chronic disease. **2020**, 10, e040207 1
- 182 Aptamer-nanoconjugates as emerging theranostic systems in neurodegenerative disorders. **2022**, 46, 100554 1
- 181 L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease. **2021**, 22, 2
- 180 A mobile-assisted voice condition analysis system for Parkinson's disease: assessment of usability conditions. **2021**, 20, 114 2
- 179 Small molecule inhibitors of  $\beta$ -synuclein oligomers identified by targeting early dopamine-mediated motor impairment in *C. elegans*. **2021**, 16, 77 2
- 178 How to optimize the effectiveness and safety of Parkinson's disease therapy? - a systematic review of drugs interactions with food and dietary supplements. **2021**, 0
- 177 LRRK2 and idiopathic Parkinson's disease.. **2022**, 8
- 176 Cohort profile: Design and implementation of the Danish Physiotherapy Research Database for patients receiving primary care with chronic disease. **2020**, 10, e040207 1
- 175 Neurochemical and Behavioral Effects of Alpha-Synuclein Oligomers in Three-Month-Old Mice. **2021**, 15, 448-453
- 174 Microglia-secreted TNF- $\alpha$  affects differentiation efficiency and viability of pluripotent stem cell-derived human dopaminergic precursors.
- 173 Sleep and circadian rhythms in Parkinson's disease and preclinical models.. **2022**, 17, 2 0
- 172 Efficacy and Evaluation of Therapeutic Exercises on Adults With Parkinson's Disease: A Systematic Review and Network Meta-Analysis.
- 171 Human Umbilical Cord Mesenchymal Stem Cells Improve Locomotor Function in Parkinson's Disease Mouse Model Through Regulating Intestinal Microorganisms.. **2021**, 9, 808905 0
- 170 Anxiety predicts impulsive-compulsive behaviours in Parkinson's disease: Clinical relevance and theoretical implications.. **2022**, 148, 220-229
- 169 Quantification of Parkinsonian Kinematic Patterns in Body-Segment Regions During Locomotion.

- 168 Graded peak cycle ergometer test for cognitively impaired patients with Parkinson's disease: a pilot study.. **2022**, 1-8
- 167 Axillary Microbiota Is Associated with Cognitive Impairment in Parkinson's Disease Patients.. **2022**, e0235821 0
- 166 Urinary Tract Infection in Parkinson's Disease.. **2022**, 0
- 165 Deriving Implications for Care Delivery in Parkinson's Disease by Co-Diagnosing Caregivers as Invisible Patients.. **2021**, 11, 3
- 164 Parkinson's disease in primary health care and nursing care: a scoping review.. **2022**, 56, e20210367
- 163 Insights into Human-Induced Pluripotent Stem Cell-Derived Astrocytes in Neurodegenerative Disorders.. **2022**, 12, 1
- 162 COMT Inhibitors in the Management of Parkinson's Disease.. **2022**, 36, 261 1
- 161 Brain Morphometry Associated With Response to Levodopa and Deep Brain Stimulation in Parkinson Disease.. **2022**, 0
- 160 PINK1 Protects against Staurosporine-Induced Apoptosis by Interacting with Beclin1 and Impairing Its Pro-Apoptotic Cleavage.. **2022**, 11, 0
- 159 Feasibility of a Multimodal Telemedical Intervention for Patients with Parkinson's Disease-A Pilot Study.. **2022**, 11, 2
- 158 Strengthening Communication and Collaboration in the Fragmented German Healthcare System: A Mixed-Method Evaluation of an Interdisciplinary Network for Parkinson's Disease.. **2022**, 0
- 157 Nutraceuticals as Modulators of Autophagy: Relevance in Parkinson's Disease.. **2022**, 23, 2
- 156 Dysautonomia in Parkinson's Disease: Impact of Glucocerebrosidase Gene Mutations on Cardiovascular Autonomic Control.. **2022**, 16, 842498 0
- 155 Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.. **2022**, 12, 2
- 154 A Critical Review of Zebrafish Models of Parkinson's Disease.. **2022**, 13, 835827 2
- 153 Microvascular Changes in Parkinson's Disease- Focus on the Neurovascular Unit.. **2022**, 14, 853372 1
- 152 A local volumetric covariance descriptor for markerless Parkinsonian gait pattern quantification. 1
- 151 A single-arm open-label pilot study of brief mindfulness meditation to control impulsivity in Parkinson's disease.. **2022**, 17, e0266354

|     |  |   |
|-----|--|---|
| 150 | Longitudinal Healthcare Utilization and Costs in Parkinson's Disease: Pre-Diagnosis to 9 Years After.. <b>2021</b> ,   | 0 |
| 149 | Exploration potenzieller Barrieren ff die Akzeptanz eines interdisziplinären sektorenbergreifenden Versorgungsnetzwerkes ff Patient*innen mit Morbus Parkinson. 1                                      |   |
| 148 | Brain-gut-microbiota axis in Parkinson's disease: a historical review and future perspective.. <b>2022</b> ,   | 3 |
| 147 | Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism.. <b>2021</b> ,   | 5 |
| 146 | Mitochondria-Microbiota Interaction in Neurodegeneration.. <b>2021</b> , 13, 776936  | 1 |
| 145 | Mitochondrial Function and Parkinson's Disease: From the Perspective of the Electron Transport Chain.. <b>2021</b> , 14, 797833  | 6 |
| 144 | Establishment of the Carrot-Made LTB-Syn Antigen Cell Line in Shake Flask and Airlift Bioreactor Cultures.. <b>2021</b> ,  |   |
| 143 | Levodopa-induced dyskinesias in Parkinson's disease increase cerebrospinal fluid nitric oxide metabolites' levels.. <b>2021</b> , 129, 55  | 0 |
| 142 | AGEomics Biomarkers and Machine Learning-Realizing the Potential of Protein Glycation in Clinical Diagnostics.. <b>2022</b> , 23,  | 0 |
| 141 | Enhancing Trial Delivery in Parkinson's Disease: Qualitative Insights from PD STAT.. <b>2022</b> ,   | 2 |
| 140 | REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson's disease: a cross-sectional and longitudinal study.. <b>2022</b> , 1 | 0 |
| 139 | Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinson's disease.. <b>2022</b> , 7, 24  | 3 |
| 138 | Women Caring for Husbands Living with Parkinson's Disease: A Phenomenological Study Protocol. <b>2022</b> , 12, 659  |   |
| 137 | Data_Sheet_1.DOCX. <b>2020</b> ,   |   |
| 136 | Image_1.JPEG. <b>2020</b> ,  |   |
| 135 | Neurologische aandoeningen /ziekte van Parkinson. <b>2022</b> , 95-108   |   |
| 134 | Wearable Immersive Virtual Reality Device for Promoting Physical Activity in Parkinson's Disease Patients.. <b>2022</b> , 22,  | 3 |
| 133 | Using a Caenorhabditis elegans Parkinson's Disease Model to Assess Disease Progression and Therapy Efficiency. <b>2022</b> , 15, 512   | 2 |

|     |   |   |
|-----|---|---|
| 132 | Novel Approach to Prognosis Parkinson's Disease with Wireless Technology Using Resting Tremors. 1   | 1 |
| 131 | Falls in Parkinson's disease: the impact of disease progression, treatment, and motor complications.  |   |
| 130 | The Role of miR-20 in Health and Disease of the Central Nervous System.. 2022, 11,  | 1 |
| 129 | Body-Worn Sensors for Parkinson's disease: A qualitative approach with patients and healthcare professionals.. 2022, 17, e0265438   | 0 |
| 128 | Exercise in Parkinson's disease. 2022, 403-412  |   |
| 127 | A cross-sectional study of Parkinson's disease and the prodromal phase in community-dwelling older adults in eastern Japan. 2022, 7, 100147   |   |
| 126 | Transposable Element Structural Variants in Parkinson's Disease: Focusing on Genotyping Alu Transposable Element Insertions with TypeTE. 2022, 43-62  |   |
| 125 | Research Hotspots and Trends of Exercise on Parkinson's Disease: A Global Bibliometric Analysis From 2012 to 2021. 2022, 16,  | 0 |
| 124 | A tissue-fraction estimation-based segmentation method for quantitative dopamine transporter SPECT.   | 0 |
| 123 | Gender differences in the prevalence of Parkinson's disease.  |   |
| 122 | Penetrance of Parkinson's disease LRRK2 G2385R-associated variant in the Chinese population.  | 1 |
| 121 | Machine Learning Classifiers to Evaluate Data From Gait Analysis With Depth Cameras in Patients With Parkinson's Disease. 2022, 16,   | 0 |
| 120 | Personalized Care in Late-Stage Parkinson's Disease: Challenges and Opportunities. 2022, 12, 813  | 0 |
| 119 | Histone Deacetylases as Epigenetic Targets for Treating Parkinson's Disease. 2022, 12, 672  | 0 |
| 118 | Neurodegeneration and Neuroinflammation in Parkinson's Disease: a Self-Sustained Loop.  | 5 |
| 117 | Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs. 3,  | 0 |
| 116 | CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson's Disease. 2022, 14, 1252   | 2 |
| 115 | Analysis of Parkinson's Disease Outpatient Counselling for Advance Directive Creation: A Cross-Sectional Questionnaire-Based Survey of German General Practitioners and Neurologists. 2022, 12, 749 | 1 |

|     |   |   |
|-----|---|---|
| 114 | The role of NURR1 in metabolic abnormalities of Parkinson's disease. <b>2022</b> , 17,  | 1 |
| 113 | Multiple N-of-1 trials to investigate hypoxia therapy in Parkinson's disease: study rationale and protocol. <b>2022</b> , 22,   | 0 |
| 112 | Bidirectional Relationship Between Sleep Disturbances and Parkinson's Disease. 13,  | 0 |
| 111 | TGFB1 rs8179181 polymorphism is reproducibly associated with Parkinson's disease in a Spanish population.   |   |
| 110 | Systematic review for the prevention and management of falls and fear of falling in patients with Parkinson's disease.  | 0 |
| 109 | The Role of Microelectrode Recording in Deep Brain Stimulation Surgery for Parkinson's Disease: A Systematic Review and Meta-Analysis. <b>2022</b> , 1-11   | 0 |
| 108 | Rhythmic auditory stimulation promotes gait recovery in Parkinson's patients: A systematic review and meta-analysis. 13,  | 1 |
| 107 | First Two-Year Observational Exploratory Real Life Clinical Phenotyping, and Societal Impact Study of Parkinson's Disease in Emiratis and Expatriate Population of United Arab Emirates 2019-2021: The EmPark Study. <b>2022</b> , 12, 1300 |   |
| 106 | Extracellular S100B inhibits A-type voltage-gated potassium currents and increases L-type voltage-gated calcium channel activity in dopaminergic neurons.   |   |
| 105 | Neurodegenerative Diseases Involve Multifactorial Interplay of Genetics and Environmental Factors. <b>2022</b> , 1-12   |   |
| 104 | Rhythmic cueing, dance, resistance training, and Parkinson's disease: A systematic review and meta-analysis. 13,  | 1 |
| 103 | Lifestyle Interventions for the Prevention of Parkinson Disease. <b>2022</b> , 99, 42-51  | 3 |
| 102 | Lipid Nanoparticles: Promising Treatment Approach for Parkinson's Disease. <b>2022</b> , 23, 9361   | 1 |
| 101 | Modeling the dynamics of innate immune response to Parkinson disease with therapeutic approach. <b>2022</b> , 19, 056004  | 0 |
| 100 | Nanostructured label-free electrochemical immunosensor for detection of a Parkinson's disease biomarker. <b>2023</b> , 252, 123838  |   |
| 99  | Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases. <b>2022</b> , 19,  | 3 |
| 98  | Role of gut microbiota-derived branched-chain amino acids in the pathogenesis of Parkinson's disease: An animal study. <b>2022</b> , 106, 307-321   | 1 |
| 97  | Application of ionic liquid to enhance the nose-to-brain delivery of etodolac. <b>2022</b> , 178, 106290  | 1 |

|    |   |   |
|----|---|---|
| 96 | Designs to Detect Disease Modification. <b>2022</b> , 1199-1218   | 0 |
| 95 | Interplay of alpha-synuclein pathology and gut microbiome in Parkinson's disease. <b>2022</b> , 159-178   | 0 |
| 94 | A Parkinsonian Digital Biomarker Learned as an Anomaly Deep Generative Representation. <b>2022</b> ,  | 0 |
| 93 | Clinical applications of exercise in Parkinson's disease: what we need to know?. 1-10   | 1 |
| 92 | Precision Medicine in Parkinson's Disease: From Genetic Risk Signals to Personalized Therapy. <b>2022</b> , 12, 1308  | 0 |
| 91 | A literature review of online handwriting analysis to detect Parkinson's disease at an early stage.   | 0 |
| 90 | Research trends and frontiers in exercise for movement disorders: A bibliometric analysis of global research from 2010 to 2021. 14,   | 0 |
| 89 | Deep brain stimulation on the external segment of the globus pallidus improves the electrical activity of internal segment of globus pallidus in a rat model of Parkinson's disease. <b>2022</b> , 1797, 148115 | 0 |
| 88 | Regarding: High Correlations Among Worldwide Prevalences of Dementias, Parkinson's Disease, Multiple Sclerosis and Motor Neuron Diseases Indicate Common Causative Factors. <b>2022</b> , 17, 263310552211298   | 0 |
| 87 | Classification Algorithms for Analyzing Parkinson's Disease Patient. <b>2022</b> ,  | 0 |
| 86 | Management of advanced Parkinson's disease in Israel: Clinicians viewpoint and action items. 14,  | 0 |
| 85 | Clinical Study of Intraoperative Microelectrode Recordings during Awake and Asleep Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease: A Retrospective Cohort Study. <b>2022</b> , 12, 1469     | 1 |
| 84 | Efficacy and evaluation of therapeutic exercises on adults with Parkinson's disease: a systematic review and network meta-analysis. <b>2022</b> , 22,   | 0 |
| 83 | Gender Differences in the Prevalence of Parkinson's disease.  | 0 |
| 82 | Lycium barbarum polysaccharide improves dopamine metabolism and symptoms in an MPTP-induced model of Parkinson's disease. <b>2022</b> , 20,   | 2 |
| 81 | Safety and effectiveness of istradefylline as add-on therapy to levodopa in patients with Parkinson's disease: Final report of a post-marketing surveillance study in Japan. <b>2022</b> , 120479               | 1 |
| 80 | Activities of Daily Living in Parkinson Disease. <b>2022</b> , 38, 285-295  | 0 |
| 79 | Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease.   | 1 |

- 78 3D biocomposite culture enhances differentiation of dopamine-like neurons from SH-SY5Y cells: A model for studying Parkinson's disease phenotypes. **2022**, 290, 121858 1
- 77 Robotic Gait Training in Specific Neurological Conditions: Rationale and Application. **2022**, 145-188 0
- 76 Inhibiting von Hippel-Lindau protein-mediated Dishevelled ubiquitination protects against experimental parkinsonism. 0
- 75 The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: A systematic review and meta-analysis. 0
- 74 Effects of Insole with Toe-Grip Bar on Barefoot Balance and Walking Function in Patients with Parkinson's Disease: A Randomized Controlled Trial. **2022**, 7, 128 0
- 73 Effects of Baduanjin exercise on motor function, balance and gait in Parkinson's disease: a systematic review and meta-analysis. **2022**, 12, e067280 1
- 72 Effects and parameters of community-based exercise on motor symptoms in Parkinson's disease: a meta-analysis. 0
- 71 Bilirubin Prevents the TH+ Dopaminergic Neuron Loss in a Parkinson's Disease Model by Acting on TNF- $\alpha$  **2022**, 23, 14276 0
- 70 Ketone Body  $\beta$ -Hydroxybutyric Acid Ameliorates Dopaminergic Neuron Injury Through Modulating Zinc Finger Protein 36/Acyl-CoA Synthetase Long-Chain Family Member Four Signaling Axis-Mediated Ferroptosis. **2023**, 509, 157-172 0
- 69 Impact of long-term care insurance on medical costs and utilization by patients with Parkinson's disease. **2023**, 317, 115563 0
- 68 Diagnosing Parkinson's disease by combining neuromelanin and iron imaging features using an automated midbrain template approach. **2023**, 266, 119814 0
- 67 Neurodegeneration in a regulatory context: The need for speed. **2023**, 33, 100383 1
- 66 A Case Report of a Patient with Parkinson's Disease Treated with Acupuncture and Exercise Therapy. **2022**, 43, 1018-1028 0
- 65 The effects of bioactive components from the rhizome of gastrodia elata blume (Tianma) on the characteristics of Parkinson's disease. 13, 0
- 64 How Well Do Rodent Models of Parkinson's Disease Recapitulate Early Non-Motor Phenotypes? A Systematic Review. **2022**, 10, 3026 0
- 63 Mitochondrial dysfunction of induced pluripotent stem cells-based neurodegenerative disease modeling and therapeutic strategy. 10, 0
- 62 Alteration of the resting-state brain networks: a multi-aspect study of functional and effective connectivity in Parkinson's disease. 0
- 61 The Interrelated Multifactorial Actions of Cortisol and Klotho: Potential Implications in the Pathogenesis of Parkinson's Disease. **2022**, 12, 1695 0

- 60 Baicalein Attenuates Brain Iron Accumulation through Protecting Aconitase 1 from Oxidative Stress in Rotenone-Induced Parkinson's Disease in Rats. **2023**, 12, 12 0
- 59 The hidden cell-to-cell trail of  $\beta$ -synuclein aggregates. **2022**, 167930 0
- 58 Exercise-Boosted Mitochondrial Remodeling in Parkinson's Disease. **2022**, 10, 3228 0
- 57 Single-nucleus co-expression networks of dopaminergic neurons support iron accumulation as a plausible explanation to their vulnerability in Parkinson's disease. 0
- 56 Psychometric properties and construct validity of the Parkinson's Disease-Cognitive Rating Scale (PD-CRS) in Colombia. 13, 0
- 55 Developmental pathways linked to the vulnerability of adult midbrain dopaminergic neurons to neurodegeneration. 15, 1
- 54 Highly Sensitive, Stretchable, and Robust Strain Sensor Based on Crack Propagation and Opening. 0
- 53 Caring for an invisible population [those with advanced Parkinson's disease]. **2022**, 105243 0
- 52 Role of  $\beta$ -synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson's disease. 2
- 51 Association of 7-Day Profiles of Motor Activity in Marital Dyads with One Component Affected by Parkinson's Disease. **2023**, 23, 1087 0
- 50 Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson's Disease. 1
- 49 4-Aminopyridine Protects Nigral Dopaminergic Neurons in the MPTP Mouse Model of Parkinson's Disease. 0
- 48 Kinases control of regulated cell death revealing druggable targets for Parkinson's disease. **2023**, 85, 101841 1
- 47 Tailoring Motor Fluctuation Treatment: Beyond Levodopa Dose Adjustment. 20-27 0
- 46 Effects and parameters of community-based exercise on motor symptoms in Parkinson's disease: a meta-analysis. **2022**, 22, 0
- 45 Antioxidative Effects of Parnassia palustris L. Extract on Ferrous Sulfate-Induced Cellular Injury of Cultured C6 Glioma Cells. **2022**, 54, 298-306 0
- 44 Parkinson's disease fluid biomarkers for differential diagnosis of atypical parkinsonian syndromes. **2023**, 3, 1
- 43 A Narrative Review of Current Status and Future Perspective of Telemedicine for Parkinson's Disease, Dementia, and Intractable Neurological Diseases in Japan. **2023**, 0



- 42 Exploring the Epigenetic Regulated Modulation of Fibroblast Growth Factor 21 Involvement in High-Fat Diet Associated Parkinson's Disease in Rats.
- 41 Evaluating the mouse neural precursor line, SN4741, as a suitable proxy for midbrain dopaminergic neurons.
- 40 Time-resolved RNA signatures of CD4+ T cells in Parkinson's disease. **2023**, 9,
- 39 Scavenging neurotoxic aldehydes using lysine carbon dots.
- 38 Gut Microbial Alteration in MPTP Mouse Model of Parkinson Disease is Administration Regimen Dependent.
- 37 A Mouse Model to Test Novel Therapeutics for Parkinson's Disease: an Update on the Thy1- $\alpha$ Syn (Tne 61) Mice.
- 36 Stroke in Parkinson's disease: a review of epidemiological studies and potential pathophysiological mechanisms.
- 35 Distressing dreams in childhood and risk of cognitive impairment or Parkinson's disease in adulthood: a national birth cohort study. **2023**, 57, 101872
- 34 Clinical Evaluation in Parkinson's Disease: Is the Golden Standard Shiny Enough?. **2023**, 23, 3807
- 33 Effect of 650 nm laser photobiomodulation therapy on the HT-7 (shenmen) acupoint in the Musculus model of Parkinson's disease. **2023**, 9, e15295
- 32 The effect of task-oriented circuit training-based telerehabilitation on upper extremity motor functions in patients with Parkinson's disease: A randomized controlled trial. **2023**, 109, 105334
- 31 Proteomic profiling reveals the potential mechanisms and regulatory targets of sirtuin 4 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's mouse model. 16,
- 30 Effects of aquatic exercise on the improvement of lower-extremity motor function and quality of life in patients with Parkinson's disease: A meta-analysis. 14,
- 29 X-Chromosome Association Study in Latin American Cohorts Identifies New Loci in Parkinson Disease.
- 28 Perspectives of people with Parkinson's disease and family carers about disease management in community settings: A cross-country qualitative study.
- 27 Levodopa Equivalent Dose of Safinamide: A Multicenter, Longitudinal, Case-Control Study. **2023**, 10, 625-635
- 26 A functional role for alpha-synuclein in neuroimmune responses. **2023**, 376, 578047
- 25 Evaluating the mouse neural precursor line, SN4741, as a suitable proxy for midbrain dopaminergic neurons.

- 24 Global, regional, and national burden of multiple sclerosis from 1990 to 2019: Findings of global burden of disease study 2019. 11, ○
- 23 Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research. **2023**, 38, 873-919 ○
- 22 The lived experience of stigma and parkinson's disease in Kenya: a public health challenge. **2023**, 23, ○
- 21 Meta-analysis of randomized controlled trials of the effects of probiotics in Parkinson's disease. ○
- 20 Ginkgolide A improves the pleiotropic function and reinforces the neuroprotective effects by mesenchymal stem cell-derived exosomes in 6-OHDA-induced cell model of Parkinson's disease. ○
- 19 Neurotrophin mimetics and tropomyosin kinase receptors: a futuristic pharmacological tool for Parkinson's. ○
- 18 Paraquat, Parkinson's Disease, and Agnotology. ○
- 17 Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach. **2023**, 23, 121-130 ○
- 16 Global Epidemiology of Movement Disorders: Rare or Underdiagnosed?. **2023**, 43, 004-016 ○
- 15 Penalized Cox Regression Analysis from Parkinson Disease to Freezing of Gait Using Multiple Kernels. **2023**, 48, 81-88 ○
- 14 Trichloroethylene: An Invisible Cause of Parkinson's Disease?. **2023**, 13, 203-218 ○
- 13 Sleep and circadian rhythms in Synucleinopathies Perspectives for disease modification. ○
- 12 3-hydroxybutyrate in the brain: Biosynthesis, function, and disease therapy. **2023**, 1, ○
- 11 Pinpointing the precise stimulation targets for brain rehabilitation in early-stage Parkinson's disease. **2023**, 24, ○
- 10 Lactobacillus plantarum CCFM405 against Rotenone-Induced Parkinson's Disease Mice via Regulating Gut Microbiota and Branched-Chain Amino Acids Biosynthesis. **2023**, 15, 1737 ○
- 9 Revisiting Alpha-Synuclein Pathways to Inflammation. **2023**, 24, 7137 ○
- 8 An upconversion nanoplatform based multi-effective treatment for Parkinson's disease. **2023**, 465, 142959 ○
- 7 PARK7/DJ-1 in microglia: implications in Parkinson's disease and relevance as a therapeutic target. **2023**, 20, ○

- 6 Effect of Physiotherapy Interventions on Motor Symptoms in People With Parkinson Disease: A Systematic Review and Meta-Analysis. 109980042311715
- 5 Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues. **2023**, 108419
- 4 Randomizing a clinical trial in neuro-degenerative disease. **2023**, 101140
- 3 Serum levels of p-tau181 in patients with Parkinson disease. **2023**, 2, 19-23
- 2 Isolating the speed factor is crucial in gait analysis for Parkinson disease. 17,
- 1 Development of Synthetic Modulator Enabling Long-Term Propagation and Neurogenesis of Human-Derived Neural Progenitor Cells.